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Statins: the high risks of discontinuation




In their mini-review/short communication in this issue of the Archives
of Medical Science, Dr. Paraskevas et al. [1] draw proper attention to the
consequences of statin discontinuation. They focus primarily on the cere-
brovascular disease but their conclusion that absolute benefits of dis-
continuation are small and the absolute risks are high is consistent with
a large and robust totality of evidence.
The Cholesterol Treatment Trialist's Collaboration [2, 3] published two
worldwide and comprehensive meta-analyses of randomized data. The
first, among about 90,000 participants in 14 randomized trials, showed
that statin therapy produced statistically significant and clinically impor-
tant reductions in myocardial infarction, stroke, cardiovascular death and
total mortality and a remarkable safety profile. The second, among 170,000
participants in 26 randomized trials, showed that further reductions by
statins in low density lipoprotein (LDL) cholesterol safely produce definite
further reductions in the incidence of myocardial infarction, stroke and
revascularization. Specifically, each 1.0 mmol/l reduction in LDL cholesterol
produces a statistically significant and clinically important reduction in the
annual rate of these major vascular events by just over 20%. There was
no evidence of any threshold within the cholesterol range studied, sug-
gesting that reduction of LDL cholesterol by 2-3 mmol/l would reduce risk
by about 40-50%. Thus, the recent randomized trials of statins using high-
er doses against lower doses as the active comparator arm have con-
tributed importantly relevant information to two long standing hypothe-
ses [4]. The first is that lower is better and the prior totality of evidence
included basic research and observational epidemiological studies, includ-
ing in rural China where the average total cholesterol is less than
3.7 mmol/l and those with total cholesterol levels that are 10% lower had
significantly decreased risks of occlusive vascular events [5]. The second
is that there is no threshold and the meta analysis of the data from ran-
domized trials with active comparators in secondary prevention contribute
importantly relevant data to this hypothesis. In terms of primary preven-
tion the JUPITER trial also contributes the most importantly relevant data
as the randomized population had no prior events and a 10 year risk of
a first CHD event of 16-18% [6]. Further, at baseline the LDL was about
3.0 and subjects assigned to 20 mg rosuvastatin achieved a greater than
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50% reduction in LDL to about 1.4. The trial was ter-
minated early after a median treatment and follow
up of about 1.9 years due to a 44% statistically
extreme reduction in the primary composite end-
point. In JUPITER there were also statistically sig-
nificant reductions in MI, stroke, and revascular-
izations and this was the first primary prevention
trial to demonstrate a statistically significant and
clinically important reduction in total all cause mor-
tality. It seems most plausible that the large reduc-
tions in LDL to levels far below those that had ever
been studied in primary prevention were critical
components of the favorable outcomes. 
In conclusion, in this issue of the Archives of
Medical Science, Dr. Paraskevas et al. contribute an
added dimension to the risks of discontinuation of
statins. The risks are high of statin discontinuation
so any decision to do so should be made by the
individual health care provider and each of his or
her patients. The general goal should be to avoid
discontinuation of statins whenever possible. 
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